Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Е. Г. Чурина, А. В. Ситникова, О. И. Уразова, V. V. Novitskiy, M. R. Patysheva, et al.
… surface of macrophages in vitro in patients with pulmonary tuberculosis, depending on the clinical form of the disease and sensitivity of the pathogen to anti-TB drugs. Materials and methods . 40 patients (36 men and 4 women) with pulmonary tuberculosis (TB) were examined: 18 pa…
Simone Villa, Giovanni Battista Migliori, Lia D’Ambrosio, Mario Raviǵlione
Tuberculosis is an infectious disease caused by bacteria of the Mycobacterium tuberculosis complex that are transmitted through air droplets from persons with pulmonary tuberculosis. Once exposed, a person might become infected but only 5–10% of them will, eventually, develop the…
Atefeh Sadeghi Shermeh, Majid Khoshmirsafa, Ali‐Akbar Delbandi, Payam Tabarsi, Esmaeil Mortaz, et al.
Introduction: Tuberculosis (TB) and especially resistant forms of it have a substantial economic burden on the community health system for diagnosis and treatment each year. Thus, investigation of this field is a priority for the world health organization (WHO). Cytokines play im…
E. S. Nikitina, O. S. Ilyina, О. Д. Баронова
…n 150 mg, pyrazinamide 375 mg) in patients with respiratory tuberculosis and preserved susceptibility of Mycobacterium tuberculosis (MTB) to anti-tuberculosis drugs. Subjects and Methods. A post-registration observational study was conducted to assess treatment effectiveness of p…
Charles Omollo, Vinayak Singh, Elizabeth Kigondu, Antonina Wasuna, Pooja Agarwal, et al.
ABSTRACT Tuberculosis (TB) is a leading global cause of mortality owing to an infectious agent, accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We aimed to identify synergistic anti-TB drug combinations with the capacity to restore therapeutic e…
Sebastian J, Thomas A, Levine C, Shrestha R, Levy S, et al.
Initial responses to tuberculosis treatment are poor predictors of final therapeutic outcomes in drug-susceptible disease, suggesting that treatment success depends on features that are hidden within a small minority of the overall infecting Mycobacterium tuberculosis population.…
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis (TB) is a serious infection that can affect the lungs and other parts of the body. The usual way to treat TB is to take 4 medicines by mouth every day for 2 months, then take 2 of the same medicines for 4 more months, for a total of 6 months. The purpose of this stud…
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, et al.
Introduction Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration. Herein we describe the design…
Radtke KK, Dooley KE, Dodd PJ, Garcia-Prats AJ, McKenna L, et al.
…ng children are particularly susceptible to severe forms of tuberculosis and poor treatment response. WHO dosing guidelines for drugs for tuberculosis treatment are based only on weight, which might lead to systematic underdosing and poor outcomes in these children. We aimed to a…
Heiman F Wertheim, PhD
Detection of M. tuberculosis in clinical specimens of children has a low sensitivity because specimens are either difficult to collect or contain low levels of M. tuberculosis. Diagnostic criteria are non-specific and culture confirmation is challenging, as sputum samples are not…
Anna Turkova, Genevieve H. Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, et al.
BACKGROUND: \nTwo thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen. \n \nMETHODS: \nWe conducted an open-label, treatment-shortening, noninferiority trial involving childr…
Omollo C, Singh V, Kigondu E, Wasuna A, Agarwal P, et al.
Tuberculosis (TB) is a leading global cause of mortality owing to an infectious agent, accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We aimed to identify synergistic anti-TB drug combinations with the capacity to restore therapeutic efficacy a…
Jumat MI, Jani J, Mustapha ZA, Rodrigues KF, Azizan N, et al.
…ist of small RNAs from three drug-susceptible Mycobacterium tuberculosis strains isolated from Sabah, Malaysia. Sputum samples were obtained from three tuberculosis patients belonging to different districts. The bacteria were detected using GeneXpert MTB/RIF, isolated and culture…
Julius Brandenburg, Jan Heyckendorf, Franziska Waldow, Nicole Zehethofer, Lara Linnemann, et al.
…'s population is infected with strains of the Mycobacterium tuberculosis complex (MTBC), the causative agents of tuberculosis (TB). In this study, we present rationally developed molecular markers for bacterial burden, which are derived from mycobacterial phospholipids. Using lip…
Goutelle S, Bahuaud O, Genestet C, Millet A, Parant F, et al.
… of RIF and 25-dRIF collected in adult patients treated for tuberculosis. Methods In adult patients receiving 10 mg/kg of RIF as part of a standard regimen for drug-susceptible pulmonary tuberculosis enrolled in the Opti-4TB study, plasma RIF and 25-dRIF concentrations were measu…
V. Guseva, I. А. Vаsilyevа, V. V. Testov
…is of effectiveness and safety of treatment for respiratory tuberculosis with confirmed drug susceptibility of M. tuberculosis using short-course regimens and a six-month regimen, based on the published data. Subjects and Methods. A systematic search for randomized and quasi-rand…
Dawson R, Diacon AH, De Jager V, Narunsky K, Moodley VM, et al.
…y in adults with smear-positive, drug-susceptible pulmonary tuberculosis. Stage 2 of this study was designed to evaluate the safety, tolerability, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both versus rifampi…
Nduagu Samuel Uchechukwu, ONYEAGWARA Ngozi Carol, Ogisi Festus Oritsemajemite, MBATA Godwin Chukwuemeka
Background: Pulmonary tuberculosis is a debilitating infectious disease that affects all age groups and sadly, a leading cause of death in developing countries particularly in sub-Saharan Africa. One major challenge facing the global efforts against tuberculosis is drug-resistanc…
John Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, Alberto Mendoza-Ticona, Samuel Pierre, et al.
…ed with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine load…
Alina Malic, Adriana Niguleanu, Tatyana Osipov
Treatment of tuberculosis (TB) includes various therapeutic regimens with a combination of at least four drugs. Adherence to the treatment regimen is crucial for efficacy outcomes based on the achievement of appropriate drug levels. Drug-resistant () strains are mainly favored by…
Pettit AC, Shepherd BE, Sterling TR
…cribes recent advances in the treatment of drug-susceptible tuberculosis (DS-TB) among people living with human immunodeficiency virus (PLWH). Recent findings Higher than standard rifampicin doses (>10 mg/kg/day) are well tolerated and have improved sterilizing activity. Standard…
Benjamin WYPLOSZ, Ph
… viability test in large cohort of smear-positive pulmonary tuberculosis patients under treatment and to determine if the test could help physicians to discontinue isolation measures in hospital setting. When patients with pulmonary tuberculosis (TB) are hospitalized for diagnos…
O.M. Shvets, О.С. Шевченко, Liliia D. TODORIKO, Olena Tovazhnyanska, Olga I. DUBYNSKA, et al.
…heral neuropathy in patients with newly diagnosed pulmonary tuberculosis during the treatment with first- and second-line antitubercular drugs, by studying the changes of plasma vitamin B1 and vitamin B12 levels. Materials and methods. The study involved 22 patients with drug-sus…
Tanner L, Evans JC, Seldon R, Jordaan A, Warner DF, et al.
Mycobacterium tuberculosis , the causative agent of tuberculosis, remains a leading infectious killer globally, demanding the urgent development of faster-acting drugs with novel mechanisms of action. Riminophenazines such as clofazimine are clinically efficacious against both dr…
Urooj Ahmad, Anab Arshad, Sara Jadoon, Shahana Saba Salih, Hafsa Ahmed, et al.
…phic characteristics of drug-susceptible and drug-resistant Tuberculosis in Khyber Pakhtunkhwa, Pakistan. Material and Methods: A retrospective survey was conducted on data from the TB Control Program Khyber Pakhtunkhwa recorded between 1st January 2021 to 3rd June 2022. 7 sentin…